A Phase II Trial of Cemiplimab, or Cemiplimab-Chemotherapy, Followed by Biomarker-guided De-escalated Curative-intent Locoregional Treatment for Patients With Advanced HPV-related Head and Neck Cancer. The MINIMA Study

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Feb 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemiplimab (Primary) ; Carboplatin; Paclitaxel
Indications Carcinoma; Head and neck cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms MINIMA

Most Recent Events

10 Jan 2022 Status changed from not yet recruiting to recruiting.
18 Nov 2021 Planned initiation date changed from 1 Oct 2021 to 1 Dec 2021.
24 Sep 2021 Planned primary completion date changed from 1 Aug 2024 to 1 Nov 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight